Summarizing, the observed tumor-specific activation, efficient control of tumor growth, and absence of xenogeneic GVHD responses in preclinical models support the translational potential of GPC-3 while novel antigens, e.g., hepatocyte growth factor-like protein (MSP) and peptide HP1 have been recognized by γδ T cells in HCC, offering potential candidates for CAR-T therapy [69]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.